In certain SCLC cases, chromatin modifiers such as CREBBP, MLLs, and ARID1A/B carry deactivating mutations with severe implications [2,3], suggesting that the modulation of the SCLC epigenetic landscape may be an attractive therapeutic option. The gene discussed is ARID1A; the disease is small cell lung carcinoma.